The CDKN1B Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the CDKN1B gene has been disrupted to create a loss-of-function model. This heterogeneous pool, generated by CRISPR/Cas9-mediated gene disruption, minimizes clonal selection biases and is particularly suited for studies of population-level phenotypic effects, including proliferation and drug response assays.
The parental Raji cell line originates from a human Burkitt’s lymphoma and is EBV-positive, retaining B cell lineage characteristics. Widely used as a B lymphocyte model for antigen presentation, immune response, and signal transduction, its rapid growth and well-characterized signaling networks make it ideal for investigating cell cycle regulation and oncogenic transformation. In this context, CDKN1B knockout enables dissection of p27Kip1 tumor-suppressive functions in lymphoid malignancy.
CDKN1B encodes p27Kip1, a cyclin-dependent kinase inhibitor that enforces G1/S arrest by binding and inhibiting cyclin E?CCDK2 and cyclin D?CCDK4/6 complexes, preventing Rb phosphorylation and E2F-dependent transcription. Its activity is governed by phosphorylation and ubiquitin-mediated proteolysis, primarily via SKP2, integrating signals from upstream pathways: FOXO transcription factors, TGF-??/SMAD2/3/SMAD4, PI3K/AKT, and MAPK/ERK (Ras?CRaf?CMEK?CERK). Downstream, p27Kip1 influences RhoA/ROCK and stathmin pathways. Key regulatory events include AKT- or ERK-mediated phosphorylation promoting 14-3-3 binding and nuclear export, and SKP2/KPC-mediated ubiquitination leading to proteasomal degradation. Thus, p27Kip1 serves as a critical node linking mitogenic and stress signals to cell proliferation.
In Raji cells, CDKN1B loss relieves the G1/S checkpoint, driving deregulated cell cycle progression, enhanced proliferation, and altered differentiation/apoptosis. Given EBV’s role in B cell immortalization, this model permits examination of viral oncoprotein interplay with p27Kip1 pathways. It enables study of p27Kip1 loss cooperation with oncogenic drivers in lymphomagenesis and its impact on CDK inhibitor sensitivity. Additionally, because p27Kip1 integrates TGF-?? and PI3K/AKT signals, the knockout offers insights into immune regulation and B cell receptor signaling, relevant to cancer and autoimmunity.
Researchers can utilize these knockout polyclonal cells in assays such as flow cytometry for cell cycle analysis, proliferation assays (MTT, BrdU), colony formation, and apoptosis detection (Annexin V). Western blotting for p27 confirms knockout, while phospho-Rb and cyclin/CDK complex analysis reveals downstream effects. Applications include drug sensitivity testing for CDK inhibitors or PI3K/AKT/mTOR agents, co-immunoprecipitation to assess altered interactions, and RT-qPCR for transcriptional changes. For immunology studies, these cells facilitate exploration of p27Kip1??s role in B cell activation and antigen presentation. For further details or custom assays, please contact Ascent Research.
